医药日报:默沙东CLESROVIMAB在华拟纳入优先审评

太平洋证券股份...
19 Jun

报告摘要市场表现:2025 年6 月18 日,医药板块涨跌幅-0.85%,跑输沪深300 指数0.97pct,涨跌幅居申万31 个子行业第22 名。各医药子行业中,体外诊断(-0.82%)、其他生物制品(-0.83%)、血液制品(-0.94%)表现居前,线下药店(-2.30%)、医药流通(-1.95%)、疫苗(-1.73%)表现居后。个股方面,日涨幅榜前3 位分别为常山药业(+14.61%)、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10